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Abstract
Mutations in GMPPB gene have been reported in patients with early-onset disease ranging from severe congenital muscular dystrophies to
limb-girdle muscular dystrophy (LGMD) with mental retardation. More recently mutations in GMPPB have been identified with congenital
myasthenic syndromes as well as milder phenotypes. We report two unrelated cases with LGMD that underwent clinical, histopathological and
genetic studies. In both cases, we found identical compound heterozygous GMPPB mutations c.79G>C p.D27H and c.859C>T p.R287W, leading
to a glycosylation defect of alpha-dystroglycan. The onset of muscle weakness was 30–40 years and the progression rate mild to moderate. Case
2 became wheelchair-bound at the age of 60. No cognitive or behavioral symptoms were noted. These cases provide further evidence that GMPPB
mutations can also cause late-onset recessive LGMD with milder phenotypes than previously reported, and thus should be considered in the
differential diagnosis of patients with adult-onset muscular dystrophies.
© 2017 Elsevier B.V. All rights reserved.
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1. Introduction
Dystroglycanopathy is a collective term for a heterogeneous
group of muscular dystrophies caused by aberrant glycosylation
of alpha-dystroglycan (α-DG), a sarcolemmal structural
membrane protein, and leading to a loss of its laminin-binding
activity [1–3]. Dystroglycanopathies have a wide clinical
spectrum from severe forms of congenital muscular dystrophies
(CMD) with brain and eye-abnormalities, to milder phenotypes
such as limb-girdle muscular dystrophy type 2I (LGMD2I). To
date, mutations in 18 genes have been associated with
glycosylation defect of α-DG and all of them but DAG1-related
mutations are known to cause secondary dystroglycanopathies
[4,5].
GMPPB gene encoding guanosine diphosphate mannose
pyrophosphorylase B protein plays an important role in the
glycosylation of proteins and lipids [6], including alpha-
dystroglycan. Mutations in GMPPB cause hypoglycosylated
α-DG with phenotypes ranging from CMD with brain and eye
abnormalities to severe intellectual disability and epilepsy to a
case resembling LGMD with only mild cognitive disability
[4,7–9]. The first reported cases had an early childhood-onset
and typically severe disease with central nervous system (CNS)
involvement. Later GMPPB-mutated adult- or adolescence-
onset LGMD with or without intellectual disability was
described [10–12]. More recently congenital myasthenic
syndromes have been associated with GMPPB mutations as well
[13,14]. In this report, we present two additional unrelated
patients with milder adult-onset LGMD without CNS
involvement caused by GMPPB mutations.
2. Case reports
2.1. Case 1
A 40-year-old woman of Swedish-Belgian descent, born to
non-consanguineous parents, with normal motor milestones
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and without prior medical history. At the age of 15, the patient
noticed poor performance in school sports without obvious
weakness or exercise intolerance. Due to persistent elevation of
liver enzymes at the age of 17, she underwent liver biopsy with
a diagnosis of unspecified hepatitis. Aged 20, she had trouble
climbing stairs and rising from the floor. On clinical
examination, aged 37, she had waddling gait with a prominent
Trendelenburg sign on the left side, left-sided scapular winging,
mild calf hypertrophy, increased lumbar lordosis, and shortness
of breath in the supine position without signs of nocturnal
hypoventilation. Muscle testing (MRC) revealed: elbow
flexion/extension and shoulder abduction 4/5, knee extension/
flexion 3+/5, hip flexion/extension and abduction 2/5, neck-
extension 4/5, neck-flexion 3+/5. Distal muscle strength was
normal. CK values were 3–5 times of the upper limit of normal
values (ULN) and liver enzymes, alanine aminotransferase and
aspartate aminotransferase, varied between 1.5 and 5 times of
ULN during the last decade. Echocardiography and 24 h-
Holter-EKG were normal. Spirometry on two occasions showed
slightly reduced forced vital capacity (78–84% predicted).
EMG showed a myopathic pattern in the proximal muscles
without spontaneous activity. By the age of 39, muscle
weakness had progressed to involve the neck muscles, and the
patient uses calipers indoor and electric scooter outdoor.
Muscle MRI showed fatty degenerative changes in lumbar
paravertebral, gluteus minimus, adductor longus, medial
gastrocnemius and less pronounced in gluteus medius,
semitendinosus, biceps femoris long head and adductor magnus
muscles, without presence of notable edema (Fig. 1). No
cognitive, behavioral, sensory, bulbar or cardiac symptoms
have been reported by the patient. Brain MRI was normal.
2.2. Case 2
A 69-year-old Finnish woman, born to non-consanguineous
parents, had unremarkable childhood and adolescence, and
negative family history. She noticed first signs of muscle
symptoms in her 30s, and progressive muscle weakness after the
age of 40 with difficulties in climbing stairs, lifting objects and in
ordinary walking but continued working until age 53. On initial
examination, proximal weakness was evident and more
pronounced in the lower limbs, gait was waddling but distal
muscle strength preserved.The calves were pseudohypertrophic.
The progression of the disease was moderate but steady; she
started to use sticks at age 53 and motorized/electrical
wheelchair at age 60. At the last examination (age 67) there was
no active movement in the pelvic muscles or in ankle dorsal and
plantar flexion. Knee extension and flexion was 2–2.5/5. Elbow
and finger extension and flexion was 4/5, but arm abduction less
than 90 degrees. There was no facial, bulbar or neck muscle
weakness, no contractures or scapular winging. EMG showed
myopathic changes and widespread spontaneous activity. CK
values were constantly elevated up to 10 times ULN and liver
enzyme alanine aminotransferase was elevated twofold.
Echocardiogram and spirometry tests showed normal results.
Cognitive or behavioral disturbances have not been noticed.
2.3. Muscle biopsy findings
2.3.1. Case 1
Biopsy from the deltoid muscle and vastus lateralis showed
fiber-size variation, and fibers containing increased amount of
internalized nuclei in both muscles. Necrotic fibers were present in
the deltoid muscle (Fig. 2A). Immunohistochemical evaluation of
dystrophin (DYS 1–3), beta-dystroglycan, spectrin, alpha-, beta-,
gamma- and delta-sarcoglycan, myotilin (all from Novocastra
NCL), merosin (Chemicon) and caveolin-3 (Santa Cruz
Biotechnology) showed normal expression. Additional
immunohistochemistry of α-DG was performed on four
occasions and each time revealed irregular patchy expression
(Fig. 2B, C). Western blot analysis (WB) was conducted for
calpain-3 and dysferlin (both from Novocastra NCL) with normal
results.WB for α-DG (Santa Cruz Biotechnology, (IIH6)) showed
a markedly reduced immunostaining (Fig. 2D). The finding
indicated a glycosylation defect of α-DG.
2.3.2. Case 2
Three muscle biopsies from both distal and proximal
muscles indicated general dystrophic changes: atrophic fibers,
necrosis, fibrosis, and excess of fat. Immunohistochemistry
performed 20 years earlier using DYS 2 antibody (Novocastra
NCL) showed uneven staining and also WB showed reduced
amount of DYS 2 leading to initial diagnosis of manifesting
female carrier of dystrophinopathy.
2.4. Molecular genetic studies
Initial genetic analyses, such as FKRP, CAPN3, DMD and
DYSF, showed normal results. Targeted next generation
sequencing was performed as previously described [15] using
version 2 of the MYOcap gene panel that is targeted to the exons
Fig. 1. Muscle imaging findings. Muscle MRI (Case 1), axial T1-weighted
images, 1.5 Tesla, illustrating lower limbs, showing fat and connective tissue
replacement in the posterior compartment of the thigh (a), especially of the
hamstring muscles and of the medial gastrocnemius (*) muscle bilaterally in the
lower leg (b).
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of 236 genes known or predicted to cause muscular dystrophy or
myopathy. A more precise description of the MYOcap gene panel
and data analysis is given in Supplementary File S1.
The analysis of the patient samples revealed compound
heterozygosity of two identical mutations in GMPPB in both
patients: mutations c.79G>C p.D27H and c.859C>T p.R287W
both previously reported [4,7,10–13]. The mutations were
verified by Sanger sequencing.
3. Discussion
GMPPB mutations were first identified in eight different
unrelated pediatric patients with severe very early-onset
muscular dystrophies, typically with CNS involvement [7].
Together with few recent reports [10–12], we can now confirm
milder adult-onset LGMD without CNS involvement caused by
compound heterozygous mutations in GMPPB. As with other
dystroglycanopathies the primary mutations lead to a
glycosylation defect of α-DG.
Interestingly, we identified in both totally unrelated cases the
identical compound heterozygous mutations. The c.79G>C
p.D27H mutation seems to be a common variant and it has been
associated with early-onset LGMD with or without epilepsy
and mental retardation [4,7], although more commonly with
milder and late-onset LGMD [10–12]. The second c.859C>T
p.R287W mutation has been previously identified in only five
patients. One of them had CMD with cerebellar involvement
[11]. Four patients had the same mutations in compound
heterozygosity as our patients; one with the disease classified as
congenital myasthenic syndrome [13] and three with LGMD
phenotype and no CNS dysfunction, disease-onset ranging
from five to 30 years [12]. Two of the latter patients underwent
muscle imaging that showed severe fatty degeneration in
paraspinal muscles, hamstring muscles and to a lesser degree in
calf muscles [12]. The affected muscles in our patient showed
the same distribution, although our patients are at the milder
end of the disease spectrum.
Cabrera-Serrano et al. [10] reported eight patients with late-
onset LGMD among five different families. Most of those
patients had some degree of cognitive and/or behavioral
symptoms or signs except patients 3 and 4 in family II, who were
clinically most similar to our cases and shared the same
pathogenic heteroallelic mutation c.79G>C. Similarly, in the
report of Carss et al. [7] the patient with the mildest phenotype
among all eight early-onset CMD/LGMD cases and the only one
without CNS signs carried the mutation c.79G>C on one allele.
In the transfection studies with the different mutations, again this
c.79G>C showed less abnormality than the ones leading to
severe CMD-CNS phenotypes [7]. These observations clearly
suggest that patients with the mutation c.79G>C have a milder
course of the disease because of less severe and only partial
glycosylation defect of α-DG observed on blots and as irregular
Fig. 2. Muscle biopsy findings. H&E-staining showing dystrophic patterns of deltoid muscle from Case 1 with fiber size-variation, and one necrotic muscle fiber
(A). Immunohistochemistry of a-dystroglycan (α-DG, Santa Cruz Biotechnology, (IIH6)) revealed irregular patchy expression (B). Normal expression of β-DG
(Novocastra NCL) demonstrates intact sarcolemma (C). Western blot analysis of α-DG shows normal expression of staining for α-DG in muscle samples from
healthy controls, while markedly reduced in Case 1 (D). Coomassie staining demonstrating similar loading of skeletal muscle proteins across samples. Muscle
samples from healthy individuals were used as positive control (C50). Protein quantity was standardized with myosin.
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patchy immunostaining label for α-DG, as shown in Case 1 and
reported by others. However, there might also be other genetic or
epigenetic factors mediating the partial glycosylation defect of
α-DG.
The presented cases provide further evidence for the
occurrence of a much milder recessive LGMD phenotype
caused by GMPPB mutations, in particular associated with the
mutation c.79G>C. Finally, we suggest that GMPPB-related
LGMD should be considered in the differential diagnosis of
patients with late-onset muscular dystrophy, especially in cases
with pathological immunostaining for α-DG and normal FKRP
gene analysis.
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